Health CareMedical Equipment and Services
  • Price (DKK)827.20
  • Today's Change-17.00 / -2.01%
  • Shares traded299.07k
  • 1 Year change-13.87%
  • Beta0.6756
Data delayed at least 15 minutes, as of Feb 06 2023 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.

  • Revenue in DKK (TTM)23.52bn
  • Net income in DKK4.63bn
  • Incorporated1957
  • Employees14.69k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Getinge AB18.47bn1.63bn41.57bn11.11k27.392.2714.772.259.159.15103.87110.280.58582.715.68--5.213.976.545.1847.4047.998.906.561.5725.030.160539.884.604.69-16.1317.85-7.3423.16
ConvaTec Group PLC14.36bn554.34m41.84bn10.03k74.963.8120.702.910.03270.03270.84820.64350.55863.116.10171,739.602.163.202.533.5954.1154.243.866.310.99372.700.475994.567.603.844.53--6.74--
Amplifon SpA15.41bn1.33bn46.94bn12.59k35.06--,390.30--4.61--6.1224.7555.818.637.24--9.02--29.1029.5911.4564.6720.1212.6530.01
Demant A/S18.66bn2.65bn50.41bn18.13k19.046.42--2.7011.4910.3781.1234.060.73282.055.311,106,131.0010.429.0718.4914.7875.1675.2314.2211.960.587945.490.62120.0023.758.33140.5013.0711.99--
Smith & Nephew plc36.08bn3.43bn87.77bn18.00k25.682.3511.762.430.46910.46914.935.130.49560.80754.13235,494.604.726.695.908.0871.0372.549.5112.340.83567.990.349152.9014.302.2216.96-7.740.80335.28
Carl Zeiss Meditec AG14.17bn2.19bn94.65bn4.22k43.356.3177.906.683.283.2821.2322.530.72922.329.92450,482.0011.349.1514.1011.2059.2657.4715.5512.382.618.920.097635.2515.559.8424.3916.9316.0014.87
Koninklijke Philips NV132.76bn-12.08bn109.22bn79.10k------0.8227-1.84-1.8220.25------------1.64--2.2540.3544.42-9.082.62--4.77----3.910.0528-366.61---1.27--
Sonova Holding AG26.96bn4.83bn112.93bn17.07k23.577.4817.104.1910.4810.4858.5533.000.65962.827.71215,544.1012.0310.5016.1913.5571.1171.8018.2417.470.841230.490.456133.6529.297.0214.2012.581.6513.85
Straumann Holding AG16.56bn3.65bn158.36bn9.88k43.5012.1035.489.563.053.0513.8410.980.73771.985.03244,616.2016.3212.9119.6315.6276.0475.1622.1218.082.3042.530.29333.3041.8017.12333.9111.5220.979.69
Coloplast A/S23.52bn4.63bn167.15bn14.69k38.8230.3729.637.1121.7521.75110.5527.800.91482.506.561,613,711.0018.0027.7328.5142.8768.6668.1219.6722.590.561212.580.789889.1816.237.77-2.474.3910.635.92
Sartorius Stedim Biotech SA25.18bn5.20bn238.68bn12.12k45.9414.1037.349.487.577.5736.6624.660.74521.838.40324,803.3015.3613.2920.5917.5852.3152.6220.6215.970.605828.210.331622.5351.1422.3823.3621.9532.3724.57
Siemens Healthineers AG161.77bn14.85bn453.95bn70.10k30.573.2518.082.811.771.7719.2416.600.48423.584.30310,328.604.485.655.947.7937.2338.899.249.850.783135.940.464652.0720.659.6918.088.1312.83--
EssilorLuxottica SA171.62bn13.28bn595.55bn186.37k44.632.1016.703.474.004.0051.6885.170.39343.518.87126,152.303.312.573.953.0362.5160.798.417.170.691225.710.268769.6737.3622.741,621.1812.4728.5010.85
Data as of Feb 06 2023. Currency figures normalised to Coloplast A/S's reporting currency: Danish Krone DKK

Institutional shareholders

11.81%Per cent of shares held by top holders
HolderShares% Held
Fundsmith LLPas of 30 Jun 20226.61m3.34%
The Vanguard Group, Inc.as of 05 Jan 20233.68m1.86%
Norges Bank Investment Managementas of 31 Dec 20213.01m1.52%
Allianz Global Investors GmbHas of 31 Dec 20222.31m1.17%
BlackRock Fund Advisorsas of 05 Jan 20231.92m0.97%
Comgest SAas of 31 Oct 20221.54m0.78%
Geode Capital Management LLCas of 02 Feb 20231.28m0.65%
Walter Scott & Partners Ltd.as of 02 Feb 20231.25m0.63%
BlackRock Advisors (UK) Ltd.as of 04 Jan 2023984.23k0.50%
Handelsbanken Fonder ABas of 31 Jan 2023804.37k0.41%
More ▼
Data from 31 Dec 2021 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.